Financial incentives may spur research and development of antibiotics for infections caused by bacteria that are resistant to current antibiotics, according to a report by the Infectious Diseases Society of America published in Clinical Infectious Diseases.
The report describes progress on IDSA’s campaign launched in 2010, “10 × ’20,” which seeks to develop 10 new, safe and efficacious systemically administered antibiotics by 2020.
Click here to read the full story on antibiotic-resistant bacteria in Becker’s ASC Review.
The U.S. is facing its second-largest measles outbreak in 25 years, with 884 confirmed cases reported, according to the latest…
Mark Clement, president and CEO of Cincinnati-based TriHealth, and a population health advocate, says it plainly: the U.S. healthcare system…
Financial uncertainty, regulatory shifts, workforce shortages, and rising supply costs are placing unprecedented pressure on healthcare leaders. As federal and…
Comments are closed.
